US03770N1019
US03770N1019
Apogee Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 285.595.000 | 216.870.000 | 31.7% | |
| Operating Income | -285.595.000 | -216.870.000 | 31.7% |
| Pretax Income | -255.565.000 | -182.128.000 | 40.3% |
| Net Income Common Stockholders | -255.843.000 | -182.146.000 | 40.5% |
| -- | -- | -- | |
| -- | -- | -- |